Human Papillomavirus Genotyping Featured
Test Code
HPV G
Associations
HPV Type 16/18, cervical cancer
Methodology
Cervista® INVADER® genotyping system
CPT Codes
Please contact a client service specialist at 800.932.2943
Turnaround Time
7-10 days
Specimen Requirements
2.0 mL liquid cytology media (ThinPrep® PAP solution or SurePath™ Test Pack solution)
Specimen Stability
Stable at 18-25°C for 21 days
Storage & Handling
Ship at ambient
Causes for Rejection
Insufficient specimen; Low sample cellularity
Reference Range
HPV HR type 16, 18 or 16/18 Detected/Not Detected
Related Content
HPV High risk detection
Description
To be used adjunctively, with an FDA approved HPV high risk test, in patients with either a HPV HR+ ASC-US result or, in women 30 years of age and older, with a HPV HR+ primary screening result.
References
- American Society for Colposcopy and Cervical Pathology
- Meijer CJ et al. (2006). Clinical utility of HPV genotyping. Gynecol Oncol. 103:12-17.
- Khan MJ et al. (2005). The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. JNCI. 97:1072-1079.
- Munoz N et al. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. NEJM. 348:518-527.
Trademarks
Invader is a registered trademark of Third Wave Technologies, Inc., a wholly-owned subsidiary of Hologic, Inc.
ThinPrep is a registered trademark of Cytyc Corportation.
SurePath is a trademark of Becton, Dickinson and Company.
ThinPrep is a registered trademark of Cytyc Corportation.
SurePath is a trademark of Becton, Dickinson and Company.